Clinical Trial Update: VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 trial comparing VSL#3 versus placebo for increasing the pathological major response rate in rectal cancer. The cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• VSL#3

Snippet

Sponsor: Catholic University of the Sacred Heart | Conditions: Rectal Cancer | Phase 3 | Status: UNKNOWN